Micronised Purified Flavonoid Fraction a Review of Its Use in Chronic Venous Insufficiency, Venous Ulcers and Haemorrhoids
Drugs 2003; 63 (1): 71-100 ADIS DRUG EVALUATION 0012-6667/03/0001-0071/$33.00/0 © Adis International Limited. All rights reserved. Micronised Purified Flavonoid Fraction A Review of its Use in Chronic Venous Insufficiency, Venous Ulcers and Haemorrhoids Katherine A. Lyseng-Williamson and Caroline M. Perry Adis International Limited, Auckland, New Zealand Various sections of the manuscript reviewed by: C. Allegra, Servizio di Angiologia, Ospedale San Giovanni, Rome, Italy; J. Bergan, Vein Institute of La Jolla, La Jolla, California, USA; E. Bouskela, Laboratório de Pesquisas em Microcirculação, Universidade do Estado do Rio De Janeiro, Rio De Janeiro, Brazil; D.L. Clement, Department of Cardiology, University Hospital, Ghent, Belgium; P.D. Coleridge Smith, Department of Surgery, University College London Medical School, The Middlesex Hospital, London, England; P. Godeberge, Unité de Proctologie Médico-Chirurgicale, Institut Mutaliste Montsouris, Paris, France; Y.-H. Ho, School of Medicine, James Cook University, Townsville, Queensland, Australia; A. Jawien, Department of Surgery, Ludwik Rydygier University Medical School, Bydgoszcz, Poland; M.C. Misra, General Surgery Department, Mafraq Hospital, Abu Dhabi, United Arab Emirates; A.-A. Ramelet, Place Benjamin-Constant, Lausanne, Switzerland; G.W. Schmid-Schönbein, Institute of Biomedical Engineering, University of California, San Diego, California, USA; F. Zuccarelli, Département Angiologie et Phlébologie, Hôpital Saint Michel, Paris, France. Data Selection Sources: Medical literature published in any language since 1980 on micronised purified flavonoid fraction, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.
[Show full text]